Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandra Tucci

Showing results (111-120 of 154) with videos related to

Pageof 16
Sort By:
Hemasphere|December 19, 2024
Early progression beyond first-line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) studyAlberto Bavieri, Maria E Nizzoli, Alessandra Tucci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 3, 2017
Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular LymphomaStefano Luminari, Angela Ferrari, Martina Manni, et al.
Blood|February 3, 2023
Targeting the immune microenvironment in Waldenström macroglobulinemia via halting the CD40/CD40-ligand axisAntonio Sacco, Vanessa Desantis, Jon Celay, et al.
Blood Advances|January 11, 2024
MYC rearrangements in HIV-associated large B-cell lymphomas: EUROMYC, a European retrospective studyChiara Pagani, Chiara Rusconi, Alessia Dalla Pria, et al.
British Journal of Haematology|June 11, 2025
Copanlisib in combination with rituximab and bendamustine for transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma patients: Results from the phase II multicentre FIL Copa-BR trial from Fondazione Italiana Linfomi (FIL)Mattia Novo, Pio Manlio Mirko Frascione, Alessia Castellino, et al.
British Journal of Haematology|February 3, 2023
Biological features and outcome of diffuse large B-cell lymphoma associated with hepatitis C virus in elderly patients: Results of the prospective 'Elderly Project' by the Fondazione Italiana LinfomiAnnalisa Arcari, Valentina Tabanelli, Francesco Merli, et al.
Blood|February 24, 2006
Splenic marginal zone lymphoma: a prognostic model for clinical useLuca Arcaini, Mario Lazzarino, Nora Colombo, et al.
Blood|July 7, 2023
Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 studyGuido Gini, Monica Tani, Alessandra Tucci, et al.
The Lancet. Oncology|July 3, 2017
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 studyAnnalisa Chiappella, Maurizio Martelli, Emanuele Angelucci, et al.
Blood|February 2, 2008
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantageMarco Ladetto, Federica De Marco, Fabio Benedetti, et al.
Pageof 16

Showing results (111-120 of 154) with videos related to

Sort By:
Pageof 16
Hemasphere|December 19, 2024
Early progression beyond first-line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) studyAlberto Bavieri, Maria E Nizzoli, Alessandra Tucci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 3, 2017
Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular LymphomaStefano Luminari, Angela Ferrari, Martina Manni, et al.
Blood|February 3, 2023
Targeting the immune microenvironment in Waldenström macroglobulinemia via halting the CD40/CD40-ligand axisAntonio Sacco, Vanessa Desantis, Jon Celay, et al.
Blood Advances|January 11, 2024
MYC rearrangements in HIV-associated large B-cell lymphomas: EUROMYC, a European retrospective studyChiara Pagani, Chiara Rusconi, Alessia Dalla Pria, et al.
British Journal of Haematology|June 11, 2025
Copanlisib in combination with rituximab and bendamustine for transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma patients: Results from the phase II multicentre FIL Copa-BR trial from Fondazione Italiana Linfomi (FIL)Mattia Novo, Pio Manlio Mirko Frascione, Alessia Castellino, et al.
British Journal of Haematology|February 3, 2023
Biological features and outcome of diffuse large B-cell lymphoma associated with hepatitis C virus in elderly patients: Results of the prospective 'Elderly Project' by the Fondazione Italiana LinfomiAnnalisa Arcari, Valentina Tabanelli, Francesco Merli, et al.
Blood|February 24, 2006
Splenic marginal zone lymphoma: a prognostic model for clinical useLuca Arcaini, Mario Lazzarino, Nora Colombo, et al.
Blood|July 7, 2023
Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 studyGuido Gini, Monica Tani, Alessandra Tucci, et al.
The Lancet. Oncology|July 3, 2017
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 studyAnnalisa Chiappella, Maurizio Martelli, Emanuele Angelucci, et al.
Blood|February 2, 2008
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantageMarco Ladetto, Federica De Marco, Fabio Benedetti, et al.
Pageof 16